GlycoMimetics Inc [GLYC] stock is trading at $3.18, up 11.58%. An important factor to consider is whether the stock is rising or falling in short-term value. The GLYC shares have gain 4.26% over the last week, with a monthly amount glided 5.30%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, March 2024, GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023. In a post published today on Yahoo Finance, Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) to be reported in Q2 2024.
From an analyst’s perspective:
GlycoMimetics Inc [NASDAQ: GLYC] stock has seen the most recent analyst activity on December 22, 2023, when CapitalOne initiated its Overweight rating and assigned the stock a price target of $12. Previously, Jefferies upgraded its rating to Buy on November 12, 2021, and elevated its price target to $4. On November 14, 2019, ROTH Capital initiated with a Buy rating and assigned a price target of $12 on the stock. SunTrust downgraded its rating to a Hold and decreased its price target to $5 on August 05, 2019. Piper Jaffray downgraded its rating to a Neutral and reduced its price target to $6 on August 05, 2019. Jefferies downgraded its rating to Hold for this stock on August 05, 2019. In a note dated April 12, 2019, Piper Jaffray initiated an Overweight rating and provided a target price of $20 on this stock.
GlycoMimetics Inc [GLYC] stock has fluctuated between $1.11 and $3.53 over the past year. GlycoMimetics Inc [NASDAQ: GLYC] shares were valued at $3.18 at the most recent close of the market.
Analyzing the GLYC fundamentals
Gross Profit Margin for this corporation currently stands at -14110.03% with Operating Profit Margin at -131253199.51%, Pretax Profit Margin comes in at -507542.84%, and Net Profit Margin reading is -752661.69%. To continue investigating profitability, this company’s Return on Assets is posted at -1.06, Equity is -1.09 and Total Capital is 1.55. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 21.74.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.93 points at the first support level, and at 2.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.30, and for the 2nd resistance point, it is at 3.43.
GlycoMimetics Inc [GLYC] reported earnings per share of -$0.14 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.14/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.13 per share as compared to estimates of -$0.18 per share, a difference of $0.05 representing a surprise of 27.80%.
Ratios To Look Out For
For context, GlycoMimetics Inc’s Current Ratio is 8.14. On the other hand, the Quick Ratio is 8.14, and the Cash Ratio is 0.01. Considering the valuation of this stock, the price to sales ratio is 20476.02, the price to book ratio is 5.33.
Transactions by insiders
Recent insider trading involved Rock Edwin, Chief Medical Officer, that happened on Sep 22 ’23 when 30403.0 shares were purchased. Chief Medical Officer, Rock Edwin completed a deal on Sep 21 ’23 to buy 35000.0 shares. Meanwhile, SVP Finance, CFO Hahn Brian M. sold 3700.0 shares on May 17 ’23.
